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Advances in treatment over recent years have increased the long-term survival of young, female cancer patients; 
unfortunately these treatments bring a significant risk of ovarian failure and infertility. This literature review aimed 
to determine the optimal technique for ovarian preservation in pre-menopausal women receiving pelvic 
radiotherapy. The traditional method comprises surgical transposition; intensity modulated radiotherapy and other 




A critical review of the evidence pertaining to pelvic radiotherapy and ovarian sparing was performed. Evidence 




 Surgical transposition appears to be a successful method of preserving ovarian function depending on the position 
of the ovaries outside of the radiation field, the age of the patient and the total dose received by the ovaries. There 
is limited modern evidence concerning its usage in relation to emerging techniques and technology. The use of 
IMRT is certainly widespread in the treatment of female pelvic cancers, however, there is no evidence supporting 
its use for reduction of ovarian dose. Several other studies have attempted to demonstrate new techniques to 
preserve ovarian function but no functional outcome measures have reinforced their results.  
 
 
Conclusions:   
Ovarian transposition has a proven track record for preservation of ovarian function but the potential value of 
IMRT as a viable alternative to date remains unexplored. New work should be encouraged to determine the 
potential value of IMRT as a non-surgical alternative.  
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Introduction 
With the advancement of new chemotherapy drugs and radiotherapy techniques, the long-term survival of young 
female cancer patients has dramatically increased.1 The major side effects of these treatments frequently include 
ovarian failure and infertility. Whole pelvic radiotherapy in particular can result in ovarian atrophy2 and reduced 
follicle stores; also known as early menopause.3 Several cancers that afflict premenopausal women, where pelvic 
radiotherapy occupies an important role in treatment, include cervical, vaginal and anorectal carcinomas, 
dysgerminoma, Hodgkin’s disease and central nervous system tumours2. For younger women with pelvic cancer, 
the resulting infertility can cause significant psychological distress.4 Doses of 5- 10Gy are commonly accepted as a 
sterilising dose for a woman in her 30’s with a 1992 paper5 reporting a steep dose response effect at 3Gy for 
induction of early menopause. A more recently published paper6 produced a model which calculated that a dose of 
2Gy is sufficient to bring about ovarian failure. The evidence does, therefore, suggest that the dose limit for ovarian 
failure differs in each patient. There is also a range of responses that are age-dependent with lowest risks seen in 
the under-25 age group.  
 
Traditionally “ovarian transposition”, in which one or both ovaries are surgically fixed outside the irradiated area 
(typically in the lateral abdomen) is used to reduce dose to the ovaries.7 The advent of Intensity-Modulated 
Radiotherapy (IMRT), however, suggests the possibility of shaping dose around the ovaries in-situ and therefore 
sparing dose without the need for surgical intervention. The current evidence does not seem to provide a clear 
answer as to which of these techniques will provide optimal outcomes for the patient; accordingly, this review aims 
to identify the most effective intervention in terms of ovarian function preservation. The review will compare and 





A literature search was performed to identify original and review articles related to ovarian function preservation 
techniques for pelvic radiotherapy. Case reports, editorials and letters were excluded. Articles were sourced from 
the main medical databases, comprising MedLine, the Science Citation Index, Scopus, ScienceDirect and CINAHL 
Plus. Search terms utilised were “ovary”, “ovarian”, “transposition”, “radiotherapy” and “pelvic IMRT”. 
Combinations of these terms using Boolean operators enabled the search to be focussed more clearly within the 
desired topics. Abstract analysis of the retrieved studies was performed and articles that were irrelevant or written 
in languages other than English were excluded. Further evidence and additional potential search terms were 
sourced from retrieved papers. A quality assessment of the papers collected was performed using the well-
validated Critical Appraisal Skills Programme (CASP) tool in order to ensure only high quality evidence was utilised. 
Articles were to be rejected if they fell too far below the relevant CASP quality criteria for the evidence type 




The search and appraisal process yielded 19 relevant articles with valid results pertinent to the research topic. 
Thematic analysis of abstracts enabled these to be grouped into three topics: “Ovarian transposition”, “IMRT” and 
“Emerging technologies”. 
Ovarian Transposition 
A range of evidence relating to ovarian transposition included phantom studies, single case studies and some dated 
clinical studies as seen in the Table. Two of these studies7,8 used assumed or estimated positions for ovarian 
transposition to estimate dose. Additionally some dated techniques were used including a 4-field pelvic “brick” and 
lead block shielding; modern advances including multi-leaf collimation and conformal planning may have yielded 
different results. Nonetheless these studies do indicate useful prediction of the ovarian dose. Haie-Meder’s study8 
was also affected by a wide range of doses and patients including cobalt and brachytherapy treatments. 
Measurements were taken using TLDs on the patient skin at an estimated position. Despite this, ovarian functions 
resumed in 79% of the patients (n=106). They concluded rather obviously that transposed ovary dose depended on 
the location of the ovaries but also, interestingly, that field arrangements did not affect this.   
 
Similar results with ovarian function preservation in 81% of patients (n= 84) was seen in a study9 where the ovaries 
were transposed bilaterally to the paracolic gutters. The dose to the ovaries in this study ranged from 0.16- 13.4 
Gy. Dose calculations in this study were also measured with TLDs but there was also a good functional assessment 
including a routine postoperative ultrasound scan and measurement of gonadotropin and E2 levels. It was noted 
that 11 patients experienced menopause at a ‘physiologic age’ (>45) and therefore it was considered to be 
independent of the mode of treatment or their cancer. This study concluded that ovarian transposition is a safe 
 and effective procedure for the preservation of ovarian function in patients ≤40 years old treated for cervical 
carcinoma by radiosurgical combination. 
Site of transposition was assessed in a study5 into 38 International Federation of Gynaecology and Obstetrics (FIGO) 
Stage 1 cervical cancer patients who underwent ovarian transposition as part of their initial operative procedure. 
Fourteen of these patients subsequently received pelvic radiotherapy and 71% of these maintained ovarian 
function. A crucial finding for this study was the importance of the placement of the ovaries, with 100% of the 
patients developing menopause if the ovaries were placed below the iliac crest.  
The remaining small sample size studies have illustrated a range of results. A 1992 study10 found only 33% of 
patients had retained ovarian function after radiotherapy; it is not clear whether this was due to poor follow-up 
attendance. Three single case studies11-13 showed success but two of these failed to note the dose received. 
Interestingly Farber’s study11 seemed to contradict earlier observations5,6,8 that deemed ovarian failure to 
commence at doses of 5Gy. 
Whilst the majority of papers relating to transposition studies appear to record moderate-to-good preservation of 
ovarian function it is important to note that surgical transposition carries some risk including compromised blood 
vessels, cyst development and possible ovarian failure.14 Despite this, all the data included in the review concluded 
that ovarian transposition is a safe and effective method used to preserve ovarian function in patients who are at 
risk of ovarian failure as a result of radiation induced ablation. It should be noted that these results were obtained 
without access to modern equipment and techniques and subsequent advance in treatment delivery may render 
the findings obsolete. There are also some methodological concerns about some of the studies with a range of 
measures and controls used. This has clearly led to a huge range in recorded ovarian doses; larger prospective 
studies with more rigorous control and well defined outcome measures would yield more reliable data.  
Intensity Modulated Radiotherapy 
Despite the rich evidence base surrounding IMRT use for avoidance of critical structures in treatment of a wide 
range of tumours, there were relatively few papers reporting its use for ovarian preservation. A 2012 paper15 
examined the evidence for IMRT in the treatment of gynaecological cancers to quantify the potential benefits of 
this new technology and to make recommendations for radiation treatment programmes that considered adopting 
this technique. Findings were based on a review of four cohort studies including a prospective study; these 
included a total of 619 patients. Acute gastrointestinal toxicity was significantly reduced by IMRT but no differences 
were seen in genitourinary toxicity. In the primary treatment of cervical cancer, the radiation dose (both EBRT and 
brachytherapy) is higher than in the post-operative setting and so the benefit of sparing normal tissue with IMRT 
would probably be greater. The paper predominantly focuses on the toxicities to the rectum, bladder and small 
bowel and makes no mention specifically of sparing the gonads. The review did highlight how the use of IMRT for 
gynaecological cancers is still in its early stages and that there are no reported randomised control trials to guide 
clinical practice for the use of IMRT for gynaecological cancers.  
A comprehensive review16 of the late and acute toxicity for the organs at risk in pelvic, mainly prostate, cancers 
considered toxicity to structures other than the bowel, rectum and bladder and recognised the need for 
established quantitative data relating to preservation of sexual function. Mention was also made of the potential 
role of IMRT and proton therapy for ovarian function preservation. Two other studies2,17 evaluated the ability of 
IMRT to reduce the general volume of healthy tissue irradiated in women with gynaecological malignancies 
receiving whole pelvic radiotherapy. Both studies found a reduction in the volume of small bowel irradiated using 
the IMRT plans compared with 3D conformal radiotherapy which resulted in excellent PTV coverage, with 
considerable sparing of normal tissues. D’Souza’s 2012 paper17 noted that IMRT plans led to significant reduction in 
dose to adjacent critical structures ranging from 26% to 41% and less acute gastrointestinal toxicities than 
conventional whole pelvic RT. Despite the paper’s focus on gynaecological tumours there was no consideration of 
dose to the ovaries, although the results clearly support the use of IMRT for critical structure sparing.  
The current literature for using IMRT as a means of preserving ovarian function is evidently sparse but logically has 
the potential to play a useful role. IMRT planning for ovarian sparing should certainly include consideration of a 
ICRU “Planning Organ at Risk Volume” margin (PRV). Like most organs, the ovaries are known to move within the 
pelvis every day, probably in relation to bladder and rectal distension. A 2012 study18 assessed the extent of 
ovarian motion to determine a range of safety volumes to help avoid ovarian ablation and premature menopause. 
They did acknowledge some key limitations of their study, including small cohort, broad age range of patients (29-
79) and wide variety of tumour sites. A more recent paper19 suggested that bilateral transposed ovaries require a 
PRV of approximately 2cm in all directions. This study produced IMRT plans with a prescribed dose of 45Gy in 25 
fractions, including an ovarian PRV, which received a maximum dose of 5Gy. The authors also acknowledged the 
need for precise contouring and appropriate margins in order to compensate for the steep dose gradients 
associated with IMRT. Given the proven value of IMRT combined with PRV use for sparing dose to a range of 
structures including bone marrow and kidneys20-21 there is a surprising lack of published evidence relating to in-situ 
ovarian-sparing IMRT.  
 Emerging Technology 
Although classed as “experimental” by some authors22 the techniques of oocyte harvesting, cryopreservation and 
ovarian transplantation may have a role to play in future ovarian preservation. These techniques, however, are 
expensive and not every female is eligible for these procedures. With the imminent deployment of proton therapy 
in the UK it is interesting to note some evidence supporting proton use for ovarian function preservation. Lee23 
compared simple proton plans with 3D-CRT, electron therapy and IMRT for three paediatric disease sites, one of 
which included pelvic sarcoma. The results demonstrated a significant reduction in dose to the ovary with protons 
for the two female patients. At all dose levels (“≥2Gy”, “5Gy” and “10Gy”) protons resulted in 0% ovarian 
irradiation compared to IMRT which resulted in 29% (at 5Gy) and 0% (at 10Gy). Despite the small sample size of 
this study the results did demonstrate positive outcomes regarding ovarian function preservation with the use of 
protons. The use of intensity-modulated proton beams is expected to further increase the dose-shaping capabilities 
of proton treatment. 
 
Discussion 
It should be acknowledged that many of the papers pertaining to ovarian transposition are over 10 years old with 
no new work being published since 2006. This might indicate that this method is outdated and has been replaced 
by more robust techniques in the clinical setting. Alternatively, it might equally be that such is the weight of 
evidence and confidence in transposition as a technique that no current studies are being pursued; it might also be 
that new techniques have attracted greater research funding.  
In addition to the age of the evidence it is clear that a variety of outcome measures have been used. A number of 
tests involving biochemical measures and ovarian imaging, so-called ovarian reserve tests, have been proposed to 
help predict ovarian reserve and/or reproductive potential. Although ovarian reserve tests have been applied 
widely, debate continues over the ability of tests currently in use to predict three related, but distinctly different, 
outcomes: oocyte quality, oocyte quantity, and fecundity.24 Future work should ensure that a range of measures 
are utilised to enable fair comparison of results.  
An emerging theme from these data is that age is an important prognostic factor for transposition with ovarian 
failure occurring with lower doses of radiation in older patients.6,8 The position of the transposed ovary was also an 
important factor in the success of the procedure, with optimal positions reported to be laterally above the iliac 
crest or as far away from the radiation field edge as possible. Therefore these factors should be considered case-
by-case for each individual and whether ovarian transposition will overall benefit the patient.  
When evaluating the role of emerging technologies for ovarian transposition, it is clear that the expense associated 
with many of these is a limiting factor. The increasingly widespread role of IMRT in clinical practice, however, does 
not appear to have extended to include ovarian preservation and it is likely to present a more cost-effective use of 
modern technology and techniques. Despite the lack of evidence supporting use of IMRT for preservation of 
ovarian function, related research25 has shown that this technology can deliver highly conformal doses to target 
tissues while avoiding specific volumes. It is clear, therefore, that IMRT, in conjunction with a PRV margin can be 
used to decrease dose to ovaries without the need for transposition and there is an urgent need for dosimetric and 
clinical studies to investigate this further. Although beyond the scope of this review, a simple retrospective 
comparative planning study would easily quantify the potential gains of IMRT and provide guidance as regards 
margins and techniques.  
 
Conclusions 
In summary this review documents that the available evidence concerning the preservation of ovarian function by 
ovarian transposition and new radiotherapy technologies is limited by small sample sizes, heterogeneity among 
study design, analyses and outcomes, and the lack of validated outcome measures. The evidence supporting 
ovarian transposition is clear but seems to have ossified around 10 years ago. The potential value of IMRT 
combined with a PRV margin for ovarian function preservation has not, as yet, been determined and new studies 
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Table: Ovarian transposition summary of evidence 
 
Study Cohort  Ovary Dose (Gy) Ovarian function (%) 
Mazonakis  (2006)(7) Phantoms 0.88-8.51 N/A 
Haie-Meder  (1993)(8) 106 0-40 (median= 1.5) 79% 
Morice  (2000)(9) 84 0.16- 13.4 81% 
Chambers  (1991)(5) 14 1.1-10.4 (mean= 3) 71% 
Anderson  (1992)(10) 24 3.1-7.7 33% 
Farber  (2005)(11) 1 5.9-7.5 100% 
Yarali  (2000)(12) 1  N/A 100% 
Schulz-Lobmeyr  (1999)(13) 1 N/A 100% 
 
 
 
